Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidamide + azacitidine + homoharringtonine + aclarubicin + cytarabine + granulocyte colony-stimulating factor
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
CAHAG is a multi-drug combination chemotherapy regimen investigated for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). It is characterized as a 'double epigenetic regimen' because it combines two epigenetic modulators—chidamide (a selective histone deacetylase inhibitor) and azacitidine (a DNA methyltransferase inhibitor)—with the HAG cytotoxic backbone. The HAG backbone consists of homoharringtonine, aclarubicin, cytarabine (Ara-C), and granulocyte colony-stimulating factor (G-CSF). This combination aims to overcome drug resistance in AML by synergistically targeting epigenetic dysregulation and inducing apoptosis in leukemic cells.
- Other names
- chidamide + azacitidine + HAG regimen
02
Targets
80S A-site (Eukaryotic ribosomal aminoacyl-tRNA site (A-site))HDAC10 (Histone Deacetylase 10)HDAC1 (Histone Deacetylase 1)CSF3R (Granulocyte colony-stimulating factor receptor)DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on chidamide + azacitidine + homoharringtonine + aclarubicin + cytarabine + granulocyte colony-stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidamide + azacitidine + homoharringtonine + aclarubicin + cytarabine + granulocyte colony-stimulating factor.